MEDICINOVA, INC. (NASDAQ:MNOV) Files An 8-K Entry into a Material Definitive AgreementItem 1.01.
On August31, 2017, MediciNova, Inc. (the “Company”) entered into a sublease agreement (the “Sublease”) with Cardinal Health 127 Inc. (the “Sublessor”) for certain premises located at 4275 Executive Square, Suite 300, La Jolla, California, consisting of approximately 4,400 square feet. The term of the Sublease commences on December1, 2017 and ends on December31, 2021. The Sublease was consented to by the master lessor. The Sublease provides that the Company will pay the Sublessor a monthly basic rent commencing with $10,958 per month with annual escalators thereafter, other than $5,479 per month for months two through five of the Sublease.
The foregoing description of the Sublease is qualified in its entirety by reference to the Sublease, which is filed as Exhibit 10.1 to this Current Report and incorporated herein by reference.
| Item 1.01. | Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit Number |
Description |
| 10.1 | Sublease, by and between the Company and Cardinal Health 127 Inc., dated August31, 2017. |
MEDICINOVA INC ExhibitEX-10.1 2 d414779dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 SUBLEASE AGREEMENT 1. Parties. This Sublease Agreement (Sublease),…To view the full exhibit click here
About MEDICINOVA, INC. (NASDAQ:MNOV)
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its MN-166 is an oral, anti-inflammatory and neuroprotective agent, which inhibits macrophage migration inhibitory factor (MIF) and certain phosphodiesterases (PDEs). Its MN-001 is an orally bioavailable small molecule compound. Its MN-221 is a highly selective B2-adrenergic receptor agonist being developed for the treatment of acute exacerbations of asthma.